The BIOCAD and Shanghai Pharmaceuticals Holding joint venture has announced the enrollment of the first Chinese patient in the Phase III international multicenter clinical trial...
New results for Phase III study of BCD-021, a bevacizumab biosimilar, were presented as a poster at the European Society for Medical Oncology (ESMO)...
Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced enrollment of the first participants in...
The R&D centre is tasked to optimise its substance manufacturing process and develop new unique molecules.
The complex has modern and high-precision equipment that allows...
Crohn's disease and ulcerative colitis are severe chronic bowel diseases for which there are no effective drugs yet. The main approach in their therapy...